Findings seen in adults with diabetes compared with both sodium-glucose cotransporter-2 and dipeptidyl peptidase-4 inhibitors
TUESDAY, Aug. 4, 2026 (HealthDay News) — Glucagon-like peptide-1 (GLP-1) receptor agonists are associated with an increased risk for alopecia in adults with type 2 diabetes, according to a study published online July 22 in The BMJ.
Huilin Tang, Ph.D., from the University of Pennsylvania in Philadelphia, and colleagues examined the association between GLP-1 receptor agonists and the risk for incident alopecia in adults with type 2 diabetes. The analysis included 12,004 GLP-1 receptor agonist initiators versus 15,221 sodium-glucose cotransporter-2 (SGLT-2) inhibitor initiators, as well as 11,964 GLP-1 receptor agonist initiators versus 11,238 dipeptidyl peptidase-4 (DPP-4) inhibitor initiators.
The researchers found that use of GLP-1 receptor agonists was associated with a higher risk for alopecia than use of SGLT-2 inhibitors (hazard ratio [HR], 1.37) or DPP-4 inhibitors (HR, 1.68). Associations persisted across sensitivity and subgroup analyses, with attenuation after negative control outcome calibration. The association was specific to nonscarring alopecia (SGLT-2 inhibitors: HR, 1.53; DPP-4 inhibitors: HR, 1.72).
“Use of GLP-1 receptor agonists was associated with an increased risk of nonscarring alopecia in adults with type 2 diabetes,” the authors write. “Although the absolute risk is low, awareness of this potential effect may help to inform treatment decisions.”
Sleep Coaching No Aid for Glucose Beyond Diabetes Lifestyle Program
Study IDs Real-World Reasons for Lemborexant Discontinuation
Weight-Loss Surgery Produces Lasting Diabetes Remission
Spinal Cord Stimulation Cuts Pain, Improves Sensation With Diabetic Nerve Damage
Mivocabtagene Autoleucel Shows Promise in Stiff Person Syndrome
Research Challenges Fusion for Lumbar Degenerative Spondylolisthesis
Ultrasound-Guided Hydrodissection Yields Improvements in Carpal Tunnel
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing